Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1) BRIEF REPORT Sarcomatoid Lung Carcinomas Show High Levels of  Programmed Death Ligand-1 (PD-L1) Vamsidhar Velcheti, MD,* David L. Rimm, MD, PhD,† and Kurt A. Schalper, MD, PhD† Programmed death-1 (PD-1) is a coinhibitory inducible receptor trials suggest that tumor PD-L1 expression predicts response present on T-cells and macrophages. Tumor cells with increased to these treatments. programmed death ligand-1 (PD-L1) are believed to escape immu- Sarcomatoid carcinoma (SC) is a rare form (0.3%–1.3% nity through activation of PD-1/PD-L1 pathway and suppression of of all lung carcinomas) of poorly differentiated non–small-cell effector-immune responses. Recent strategies targeting the PD-1/ lung carcinoma (NSCLC) containing a component of malignant PD-L1 axis have shown promising results in patients with several mesenchymal differentiation. According to the last World Health tumors types, including lung carcinomas. Preliminary data suggest Organization classification, SCs comprise five histopathologic that PD-L1 protein expression might have predictive response to subtypes: pleomorphic carcinoma (PC), spindle-cell carcinoma such therapies. Sarcomatoid carcinomas (SCs) of the lung include (SCC), giant cell carcinoma (GCC), carcinosarcoma, and rare subtypes of poorly differentiated non–small-cell lung carcino- pulmonary blastoma. Combined lesions (e.g., PC) include areas mas of high grade and aggressive behavior. The biology of these of conventional NSCLC (e.g., squamous, adenocarcinoma, neoplasms is poorly understood and they frequently show http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

Schalper, Kurt A.
Journal of Thoracic Oncology , Volume 8 (6) – Jun 1, 2013
Download PDF
3 pages

Loading next page...
 
/lp/wolters-kluwer-health/sarcomatoid-lung-carcinomas-show-high-levels-of-programmed-death-lvhgxYpz54

References (15)

Copyright
Copyright © 2013 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0b013e318292be18
pmid
23676558
Publisher site
See Article on Publisher Site

Abstract

BRIEF REPORT Sarcomatoid Lung Carcinomas Show High Levels of  Programmed Death Ligand-1 (PD-L1) Vamsidhar Velcheti, MD,* David L. Rimm, MD, PhD,† and Kurt A. Schalper, MD, PhD† Programmed death-1 (PD-1) is a coinhibitory inducible receptor trials suggest that tumor PD-L1 expression predicts response present on T-cells and macrophages. Tumor cells with increased to these treatments. programmed death ligand-1 (PD-L1) are believed to escape immu- Sarcomatoid carcinoma (SC) is a rare form (0.3%–1.3% nity through activation of PD-1/PD-L1 pathway and suppression of of all lung carcinomas) of poorly differentiated non–small-cell effector-immune responses. Recent strategies targeting the PD-1/ lung carcinoma (NSCLC) containing a component of malignant PD-L1 axis have shown promising results in patients with several mesenchymal differentiation. According to the last World Health tumors types, including lung carcinomas. Preliminary data suggest Organization classification, SCs comprise five histopathologic that PD-L1 protein expression might have predictive response to subtypes: pleomorphic carcinoma (PC), spindle-cell carcinoma such therapies. Sarcomatoid carcinomas (SCs) of the lung include (SCC), giant cell carcinoma (GCC), carcinosarcoma, and rare subtypes of poorly differentiated non–small-cell lung carcino- pulmonary blastoma. Combined lesions (e.g., PC) include areas mas of high grade and aggressive behavior. The biology of these of conventional NSCLC (e.g., squamous, adenocarcinoma, neoplasms is poorly understood and they frequently show

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Jun 1, 2013

There are no references for this article.